The FDA emits an alert for type 2 diabetes medications.
A certain type of medications for type 2 diabetes could lead to a potentially deadly condition called ketoacidosis , according to the administration of food and food from the United States (U.S. Food and Drug Administration, or FDA).
These medicines are sold under the names invokana (canagliflozine), invokamet (canagliflozine and metformin), pharxiga (dapagliflozine), xigduo xr (dapagliflozine and prolonged release metformin), Jardiance (picaggliflozine), glyxambi (piccogliflozine and linagliptine).
Between March 2013 and June 2014, the FDA received 20 reports that these drugs triggered ketoacidosis, a condition in which blood acid levels called ketones rise too much.
If not, ketoacidosis can lead to a diabetic coma or even death, according to the American Diabetes Association (American Diabetes Association).The 20 patients had to go to an emergency department or be hospitalized, according to the FDA.
